Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma

International Journal of Cancer

Volumn 127, Issue 4, 2010, Pages 968-976

  Lee, Nikki P ^a   Tsang, Felice H ^a   Shek, Felix H ^a   Mao, Mao ^b,d   Dai, Hongyue ^b   Zhang, Chunsheng ^b   Dong, Suisui ^a   Guan, Xin Yuan ^a   Poon, Ronnie T P ^a   Luk, John M ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b ROSETTA INPHARMATICS   (United States)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d PFIZER INC   (United States)

Author keywords

eIF5A; Hepatocellular carcinoma; Hypusination; Oncofetal molecule; Targeted therapy

Indexed keywords

ANTIMITOTIC AGENT; COMPLEMENTARY DNA; DEOXYHYPUSINE HYDROXYLASE; DEOXYHYPUSINE SYNTHASE; INITIATION FACTOR 5A; INITIATION FACTOR 5A1; INITIATION FACTOR 5A2; ISOPROTEIN; N1 GUANYL 1,7 DIAMINOHEPTANE; OXYGENASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; INITIATION FACTOR; MESSENGER RNA; RNA BINDING PROTEIN; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CATALYSIS; CELL PROLIFERATION; CELL STRAIN HEPG2; COHORT ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPUSINATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; MITOSIS INHIBITION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROCESSING; RNA INTERFERENCE; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; GENE EXPRESSION PROFILING; GENETICS; LIVER CELL; LIVER TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WOUND HEALING;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELLS, CULTURED; COHORT STUDIES; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDE INITIATION FACTORS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; WOUND HEALING;

EID: 77954743971     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25100     Document Type: Article

References (37)

1. Park MH. The post-translational synthesis of a polyamine-derived amino acid, hypusine, in the eukaryotic translation initiation factor 5A (eIF5A). J Biochem (Tokyo) 2006;139(2):161-9.
2. Wolff EC, Kang KR, Kim YS, Park MH. Posttranslational synthesis of hypusine: evolutionary progression and specificity of the hypusine modification. Amino Acids 2007;33:341-50.
3. Zanelli CF, Valentini SR. Is there a role for eIF5A in translation? Amino Acids 2007;33(2):351-8.
4. Shi XP, Yin KC, Zimolo ZA, Stern AM, Waxman L. The subcellular distribution of eukaryotic translation initiation factor, eIF-5A, in cultured cells. Exp Cell Res 1996;225(2):348-56. (Pubitemid 26183952)
5. Parreiras-e-Silva LT, Gomes MD, Oliveira EB, Costa-Neto CM. The N-terminal region of eukaryotic translation initiation factor 5A signals to nuclear localization of the protein. Biochem Biophys Res Commun 2007;362(2):393-8.
6. Lee SB, Park JH, Kaevel J, Sramkova M, Weigert R, Park MH. The effect of hypusine modification on the intracellular localization of eIF5A. Biochem Biophys Res Commun 2009;383(4):497-502.
7. Clement PM, Johansson HE, Wolff EC, Park MH. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J 2006;273(6):1102-14.
8. Nishimura K, Murozumi K, Shirahata A, Park MH, Kashiwagi K, Igarashi K. Independent roles of eIF5A and polyamines in cell proliferation. Biochem J 2005;385(Pt 3):779-85. (Pubitemid 40208839)
9. Jasiulionis MG, Luchessi AD, Moreira AG, Souza PP, Suenaga AP, Correa M, Costa CA, Curi R, Costa-Neto CM. Inhibition of eukaryotic translation initiation factor 5A (eIF5A) hypusination impairs melanoma growth. Cell Biochem Funct 2007;25(1):109-14. (Pubitemid 46121789)
10. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, Lowe SW. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007;21(24):3232-7.
11. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004;10(5):484-6.
12. Lee JW, Choi JJ, Lee KM, Choi CH, Kim TJ, Lee JH, Kim BG, Ahn G, Song SY, Bae DS. eIF-4E expression is associated with histopathologic grades in cervical neoplasia. Hum Pathol 2005;36(11):1197-203. (Pubitemid 41540396)
13. Lee NP, Leung KW, Cheung N, Lam BY, Xu MZ, Sham PC, Lau GK, Poon RT, Fan ST, Luk JM. Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma. Proteomics 2008;8(10):2136-49. (Pubitemid 351775792)
14. Sun S, Lee NP, Poon RT, Fan ST, He QY, Lau GK, Luk JM. Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Liver Int 2007;27(8):1021-38. (Pubitemid 47399436)
15. Lee NP, Cheung ST, Poon RT, Fan ST, Luk JM. Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomarkers Med 2007;1:273-84.
16. Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, Lau GK, Beretta L, Fan ST. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics 2008;7(2):315-25. (Pubitemid 351298446)
17. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, et al. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 2009;50:1453-63.
18. Lee YB, Folk JE. Branched-chain and unsaturated 1,7-diaminoheptane derivatives as deoxyhypusine synthase inhibitors. Bioorg Med Chem 1998;6(3):253-70.
19. Park MH, Wolff EC, Lee YB, Folk JE. Antiproliferative effects of inhibitors of deoxyhypusine synthase. Inhibition of growth of Chinese hamster ovary cells by guanyl diamines. J Biol Chem 1994;269(45):27827-32.
20. Shi XP, Yin KC, Ahern J, Davis LJ, Stern AM, Waxman L. Effects of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on the growth of tumorigenic cell lines in culture. Biochim Biophys Acta 1996;1310(1):119-26. (Pubitemid 3023350)
21. Lee NP, Chen L, Lin MC, Tsang FH, Yeung C, Poon RT, Peng J, Leng X, Beretta L, Sun S, Day PJ, Luk JM. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J Proteome Res 2009;8(3):1293-303.
22. Lee NP, Mruk DD, Xia W, Cheng CY. Cellular localization of sphingomyelin synthase 2 in the seminiferous epithelium of adult rat testes. J Endocrinol 2007;192(1):17-32.
23. Lee NP, Tong MK, Leung PP, Chan VW, Leung S, Tam PC, Chan KW, Lee KF, Yeung WS, Luk JM. Kidney claudin-19: localization in distal tubules and collecting ducts and dysregulation in polycystic renal disease. FEBS Lett 2006;580:923-31.
24. Lee NP, Tsang S, Cheng RH, Luk JM. Increased solubility of integrin bA domain using maltose-binding protein as a fusion tag. Protein Pept Lett 2006;13(5):431-5.
25. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4(2):249-64.
26. Kim do Y, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, Lee KS, Chon CY, Han KH. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007;72Suppl 1:52-7.
27. Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 2008;95(5):611-19.
28. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006;4(1):111-7.
29. Lai KK, Kolippakkam D, Beretta L. Comprehensive and quantitative proteome profiling of the mouse liver and plasma. Hepatology 2008;47(3):1043-51.
30. Huang Y, Higginson DS, Hester L, Park MH, Snyder SH. Neuronal growth and survival mediated by eIF5A, a polyamine-modified translation initiation factor. Proc Natl Acad Sci U S A 2007;104(10):4194-9.
31. Feng JT, Shang S, Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene 2006;25(27):3810-7.
32. Hauber I, Bevec D, Heukeshoven J, Kratzer F, Horn F, Choidas A, Harrer T, Hauber J. Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J Clin Invest 2005;115(1):76-85.
33. Balabanov S, Gontarewicz A, Ziegler P, Hartmann U, Kammer W, Copland M, Brassat U, Priemer M, Hauber I, Wilhelm T, Schwarz G, Kanz L, et al. Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 2007;109(4):1701-11.
34. Wu H, Pan CL, Yao YC, Chang SS, Li SL, Wu TF. Proteomic analysis of the effect of Antrodia camphorata extract on human lung cancer A549 cell. Proteomics 2006;6(3):826-35.
35. Bian XW, Xu JP, Ping YF, Wang Y, Chen JH, Xu CP, Wu YZ, Wu J, Zhou XD, Chen YS, Shi JQ, Wang JM. Unique proteomic features induced by a potential antiglioma agent, Nordy (dl-nordihydroguaiaretic acid), in glioma cells. Proteomics 2008;8(3):484-94.
36. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol 2008;48(5):858-79.
37. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008;135(5):852-864.